Maxigen Biotech Inc
TWSE:1783

Watchlist Manager
Maxigen Biotech Inc Logo
Maxigen Biotech Inc
TWSE:1783
Watchlist
Price: 52 TWD 0.58%
Market Cap: 4.6B TWD
Have any thoughts about
Maxigen Biotech Inc?
Write Note

Maxigen Biotech Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Maxigen Biotech Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Maxigen Biotech Inc
TWSE:1783
Long-Term Debt
NT$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Grape King Bio Ltd
TWSE:1707
Long-Term Debt
NT$117.1m
CAGR 3-Years
-28%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
Maywufa Co Ltd
TWSE:1731
Long-Term Debt
NT$561.9m
CAGR 3-Years
22%
CAGR 5-Years
13%
CAGR 10-Years
11%
Chlitina Holding Ltd
TWSE:4137
Long-Term Debt
NT$1.3B
CAGR 3-Years
-5%
CAGR 5-Years
30%
CAGR 10-Years
N/A
No Stocks Found

Maxigen Biotech Inc
Glance View

Market Cap
4.6B TWD
Industry
Consumer products

Maxigen Biotech, Inc. engages in the research, development, manufacturing, and sales of biomedical materials and beauty care products. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2011-05-18. The firm operates through two main segments. The Consumer Products segment is mainly engaged in the wholesales of cleansing products, facial care products, medical beauty products and others. The Biomedical Products is mainly involved in the manufacture and sales of Formagraft collagen and ceramic composite material products, Foramic ceramic bone feed materials, Artiaid hyaluronic acid joint injection products, ViscAid ophthalmology viscoelastic agents, as well as SurgiAid wound collagen materials and others.

Intrinsic Value
30.34 TWD
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Maxigen Biotech Inc's Long-Term Debt?
Long-Term Debt
0 TWD

Based on the financial report for Sep 30, 2024, Maxigen Biotech Inc's Long-Term Debt amounts to 0 TWD.

Back to Top